Skip to main content
. 2021 May 13;34(4):337–341. doi: 10.37201/req/045.2021

Table 3.

Additional antiviral and anti-inflammatory treatments.

Treatments received (%) N (%)
Hydroxychloroquine 31 (100)
Lopinavir/ritonavir 31 (100)
Azithromycin 26 (83.9)
Remdesivir 5 (16.1)
Interferon 1 (3.2)
Steroid therapy 18 (58.1)
Steroid therapy prior to siltuximab 11 (35.5)
Tocilizumab 8 (25.8)
Tocilizumab prior to siltuximab 7 (22.58)
Days from tocilizumab administration to siltuximab (IQR) 2 (1-3)
Anakinra 7 (22.6)
Anakinra after siltuximab administration 6 (19.4)